美国MDxHealth  
MDxHealth是一家分子诊断公司，开发和销售先进的测试为癌症患者评估和个性化的治疗。

申请专利的DNA甲基化平台和生物标志物，我们帮助解决庞大且不断增长的未满足的医疗需求，为更好的癌症诊断和治疗的信息。

MDxHealth是一个公开上市的公司在纽约泛欧交易所集团（在纽约证券交易所，纽约证券交易所）代号“MDXH”布鲁塞尔和阿姆斯特丹的市场交易。

MDxHealth（原名Oncomethylome Sciences公司）成立于2003年，总部设在比利时。其美国总部位于北卡罗来纳州达勒姆。

MDxHealth自身或与制药公司合作开发分子诊断产品。其部分产品已经商业化和公司的其他产品有广泛的管道为主要癌症的迹象。

MDxHealth is a molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and the personalized treatment of patients.

Applying our patented DNA methylation platform and biomarkers, we help address a large and growing unmet medical need for better cancer diagnosis and treatment information.

MDxHealth is a publicly-listed company trading on the NYSE Euronext (NYSE as in New York Stock Exchange) markets of Brussels and Amsterdam under the ticker symbol "MDXH".

MDxHealth (formerly OncoMethylome Sciences) was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Durham, NC.

MDxHealth develops molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.